dshell and bubba, seems logical to me that there are manufacturing contracts in place by now. All you need to do is read the 12-21-09 PR. A majority of the paragraphs are related to having a product in hand. Plus if you read the 10/22/09 PR the manufacturing deals were already being worked on in Korea throughout 2009. That is why I'd bet that manufacturing contracts are likely in place and the Harp is already in the startup production phase.
SUN VALLEY, CA -- (Marketwire) -- 10/22/09 --
XTend Medical (PINKSHEETS: XMDC), a company specializing in manufacturing and distributing the latest in telemedicine and diagnostic devices, released the following information regarding the company's progress on merger and company's progress:
"XTend would like to update our shareholders on our progress to date. Mr Lee from BioHarp, Korea traveled to Los Angeles last weekend to meet with the executives of XTend. The meetings were very positive and included several aspects in the manufacturing process and the business model moving forward. I personally want to thank Mr. Lee for his dedication and efforts in moving the merger forward. The management of XTend will be traveling to Korea soon to meet with the executives of BioHarp, Korea to finalize the merger. We also intend to secure the manufacturing relationships Mr. Lee has worked on over the past months in order to fulfill our needs for the BioHarp unit. Mr. Lee has identified several major manufacturers that can handle the volume of devices we'll need to fulfill the commitments we expect over the next 6-12 months and having strategic manufacturing partners in Korea to work closely with the technical staff is imperative to the success of the company. While in Korea, XTend management will also be looking to secure a listing on the Korean Stock Exchange that will add to our shareholder base on a global basis and gain additional exposure for the company
SUN VALLEY, CA -- (Marketwire) -- 12/21/09 --
XTend Medical, (PINKSHEETS: XMDC), a company that specializes in delivering life changing medical technology to healthcare organizations globally, released the following information to update their shareholders on the company's operational plans moving forward:
"Now that we've completed the purchase of the BioHarp, the company has a clear path it will take to deliver this cutting-edge product to the healthcare community globally. Our intentions are to do the following:
1. Finalize the end product design relating to the device and software
This has already been agreed upon by management and we will look to have the finished product very shortly to begin sales to the veterinary, equine, and horticulture sectors
2. Secure our manufacturing contracts so we can meet our anticipated needs of 20-30,000 units per month for 2010. (This number could rise dramatically based on our current contract conversations with several health organizations globally.)
3. Amend our KFDA application with the adjustments made to the device and software. Expected approval is within six-eight weeks for anticipated sales in South Korea
4. Initialize programs with several cancer centers, early disease detection clinics, and children's hospitals in the U.S. to establish the necessary criteria for submission to the FDA
5. Establish our training standards to create jobs wherein Certified BioHarp technicians can be deployed to hospitals, clinics, and healthcare groups in the U.S. and other countries. This will assist the company in creating opportunities for individuals to be trained and gain successful employment for years to come, either as an employee or for outside healthcare companies
6. Work closely with several global universities that have expressed a desire to utilize the BioHarp in their studies of crops and plant growth, thereby establishing the BioHarp's efficacy in assisting nations in their food and fuel productivity through proper scanning using the BioHarp device
7. Focus on completing the company's audited financials within the first quarter of 2010 in order to gain a listing on a higher exchange. The company is currently interviewing auditors in order to accomplish the audit in a timely manner
Our goal is to focus on immediate sales as well as planning the future of the company wherein we capitalize on the many opportunities the BioHarp can bring to XTend Medical," stated Mr. Paul D. Lisenby, CEO of XTend Medical
News 
Market Data 
Discover 
